Expedition Therapeutics

Expedition develops novel therapies for serious inflammatory and respiratory diseases. Its lead program is a next-generation once-daily DPP1 inhibitor.

Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series B
Initial Investment Year
2026
Expedition Tx Hover Image